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Purpose. To determine the efficacy of 23-gauge pars plana vitrectomy (PPV) for symptomatic posterior vitreous detachment (PVD)
on visual acuity (VA) and quality after multifocal intraocular lenses (IOLs).Methods. In this prospective case series, patients who
developed symptomatic PVD and were not satisfied with visual quality due to floaters and halos after multifocal IOL implantation
underwent PPV. Examinations included LogMAR uncorrected visual acuity (UCVA), intraocular pressure, biomicroscopy, and
indirect ophthalmoscopy at baseline and 1, 7, 30, and 180 days postoperatively. Ultrasonography and aberrometry were performed.
The Visual Functioning Questionnaire 25 (VFQ-25) was administered preoperatively and at 30 days postoperatively. Both the
postoperative UCVA and questionnaire results were compared to preoperative findings using the Wilcoxon test. Results. Sixteen
eyes of 8 patients were included. VA significantly improved from 0.17 to 0.09 postoperatively (𝑃 = 0.017). All patients reported
improvement of halos, glare, and floaters. VFQ-25 scores significantly improved in general vision (𝑃 = 0.023), near activities
(𝑃 = 0.043), distance activities (𝑃 = 0.041), mental health (𝑃 = 0.011), role difficulties (𝑃 = 0.042), and driving (𝑃 = 0.016).
Conclusion. PPVmay increase UCVA and quality of vision in patients with bilateral multifocal IOLs and symptomatic PVD. Larger
studies are advised.
1. Introduction
Posterior vitreous detachment (PVD) is defined as the sep-
aration of the posterior hyaloid from the internal limiting
membrane [1]. It is age-related and becomes noticeable after
the sixth decade of life (up to 63% prevalence) and is related
to synchysis senilis [2]. Vitreous separation can cause visual
symptoms such as photopsia from vitreoretinal traction and
floaters resulting from the presence of condensed vitreous
collagen [3]. About 30% of patients have floaters after
development of PVD; however, most patients tolerate their
symptoms [1, 2, 4]. A minority of patients report that these
floaters are troublesome, in particular young myopic patients
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and those whose work requires detailed visual tasks. Pseu-
dophakic patients frequently report floaters, which may be
explained by the improved postoperative contrast sensitivity
related to the intraocularmonofocal lens, which increases the
perception of floaters in the visual field [2, 4]. PVD incidence
is also increased after cataract surgery by phacoemulsification
with implantation of a posterior chamber intraocular lens
(IOL) [4].
Multifocal IOLs were designed to reduce the need for
spectacles by providing two or more points of focus. Adverse
effects include reduced contrast sensitivity and the subjective
experience of halos around lights [5].
The apodized diffractivemultifocal AcrySof ReSTOR IOL
(Alcon, Fort Worth, TX) was designed specifically to reduce
glare and halos and provide increased dominant distance
vision for patients with large pupils [5].This lens has a central
3.6mm apodized optic area with 12 concentric diffractive
zones on the anterior surface for gradual reduction of the
diffractive increments from the center to the periphery [6].
Rayner M-flex multifocal IOLs (Rayner, London, UK) are
based on multizoned refractive aspheric optic technology,
with either four or five annular zones (depending on the IOL
base power [7, 8]).
Themultifocal IOLdesignwith concentric rings of optical
zones creates positive dysphotopsias, also called photic phe-
nomena. Visual phenomena interfering with vision strongly
affect patient satisfaction [9]. Tolerance to visual phenom-
ena caused by multifocal IOLs usually improves over time.
Researchers believe the brain adjusts to the altered visual
input over time through neural adaptation [9]. To experience
the full visual benefits of multifocal IOLs, most patients
require a neuroadaptation period of about 6 months [10, 11].
In the present study, the authors investigated the role
of sutureless pars plana vitrectomy treatment in patients
with symptomatic PVD in terms of visual acuity (VA) and
visual satisfaction (measured through a standardized ques-
tionnaire) in patients who previously underwent bilateral
implantation of the ReSTOR +3 (Alcon, Fort Worth, TX) or
the M-Flex IOLs (Rayner, London, UK).
2. Methods
This prospective case series included patients who were not
satisfied with their VA and complained of halos, glare, and
floaters for at least 6 months after having undergone bilateral
phacoemulsification using a 2.2mmmicroincision technique
and implantation of ReSTOR +3 (Alcon, Fort Worth, TX) or
M-Flex IOLs (Rayner, London, UK).
Patients underwent a complete preoperative ophthal-
mologic examination including evaluation of refractive sta-
tus, measurement of far uncorrected VA (UCVA) and
best-corrected VA (BCVA), slit-lamp examination, Gold-
mann applanation tonometry, and indirect ophthalmoscopy.
Ultrasonography, automated visual field measurement using
the Humphrey 750i Visual Field Analyzer (Zeiss, Ger-
many), and optical coherence tomography (OCT, Spec-
tralis OCT, Heidelberg, Germany) were also performed, as
well as a corneal aberrometry measurement (Galilei Dual
ScheimpflugAnalyzer, ZiemerOphthalmology, Switzerland).
The National Eye Institute Visual Function Questionnaire 25
(NEI VFQ-25) was administered before and 30 days after
pars plana vitrectomy (PPV). All eyes were submitted to
YAG-laser capsulotomy (Alcon,USA) at distinct periods after
cataract surgery. Patients were informed about the possibility
of being submitted to a sutureless PPV surgery to clear media
opacities to obtain better focus of the multifocal IOL on the
retina. All patients provided informed consent for sutureless
23-gauge PPV assisted by triamcinolone acetonide.The study
protocol was approved by the Ethics Committees of the
Federal University of Sa˜o Paulo. The study was conducted
according to the Declaration of Helsinki.
Patients were evaluated on postoperative days 1 and 7
and at 1, 3, and 6 months postoperatively. Ultrasonography
was repeated at 7 days and 1 month after surgery. A new
aberrometry was performed 6 months postoperatively.
Patients were included in the study if they were pre-
viously submitted to cataract surgery with multifocal IOL
implantation and had been diagnosed with symptomatic
PVD of at least 6 months of duration. Symptomatic PVD
was defined as PVD detected by indirect ophthalmoscopy
and fundus biomicroscopy revealing vitreous debris (which
could include a Weiss Ring but that was not mandatory) in
a patient with PVD-related visual symptoms (floaters and/or
photopsias). Additionally, ultrasonography had to disclose
PVD in the axial, temporal, nasal, inferior, and superior
planes. The refractive error based on objective and subjective
dynamic refraction could not exceed ±0.25 of spherical and
no cylindric refractive errors. Patients also had to have
aberrometry showing a root mean square (RMS) of less
than 1.2 in both eyes. In addition, macular/retinal diseases
had to be ruled out by spectral-domain OCT, fluorescein
angiography, and automated visual fields (patients excluded
if mean deviation values were not between +1.00 and −7.00
decibels).
Exclusion criteria were diabetes mellitus, age less than
45 years, a previous stroke or neurosurgical procedure, glau-
coma or uveitis, previous ocular surgery other than cataract
and multifocal IOL implantation, intraoperative complica-
tions during a previous phacoemulsification such as capsular
tears, previous corneal diseases or scars, irregular corneal
astigmatism, iris abnormalities, macular degeneration, neu-
roophthalmic disease, and postoperative complications such
as macular edema and retinal detachment.
Vitreoretinal surgeries were performed by the same
experienced surgeon (MM). Four-port PPV using three
23-gauge valved trocars (DORC, Amsterdam, Netherlands)
was performed. A Tornambe (Synergetics, Missouri, USA)
chandelier light pipe connected to a Photon II light source
(Synergetics, MO, USA) was inserted into an additional 25-
gauge sclerotomy. The surgical procedure was performed
using the Stellaris PC vitrectomy system (Bausch & Lomb,
USA) and a standard 23-gauge vitrectomy probe and the
binocular indirect ophthalmomicroscope (BIOM) (Oculus,
Germany) for visualization of the vitreous cavity. A core
vitrectomy was performed using 5,000 cuts/minute and an
aspiration rate of 200mmHg for approximately 5minutes fol-
lowed by central posterior capsulectomy. In all cases, a flush
of 0,3mL of triamcinolone acetonide 4mg/mL (Ophthalmos,
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Table 1: Baseline patients’ characteristics and uncorrected visual acuity testing in both eyes prior to and after 23-gauge sutureless pars plana
vitrectomy.
Patient Gender Age(years)
Time interval
between
symptoms onset
and PPV
(months)
Eye
Preoperative
UCVA
(logMAR)
Postoperative
UCVA
(logMAR)
Preoperative
corneal
aberrometry
(RMS)
Postoperative
corneal
aberrometry
(RMS)
Preoperative
OCT central
foveal
thickness
(𝜇m)
Preoperative
automated
visual field
MD (dB)
1 F 67 12 OD 0.17 0.17 1.1 1.1 226 −1.68
OS 0.17 0.17 1.0 1.0 246 −1.54
2 M 58 12 OD 0.30 0.09 1.1 1.1 250 −1.0
OS 0.30 0.09 1.1 1.0 227 −0.5
3 F 54 6 OD 0.09 0.00 0.8 0.7 260 −0.2
OS 0.09 0.00 0.8 0.8 264 −0.4
4 M 44 8 OD 0.09 0.00 0.4 0.4 246 −1.0
OS 0.09 0.00 0.6 0.5 249 −0.5
5 F 50 7 OD 0.30 0.17 0.4 0.3 232 +0.5
OS 0.30 0.17 0.5 0.4 230 0.0
6 M 62 10 OD 0.09 0.09 1.0 1.0 228 −2.92
OS 0.09 0.09 1.1 1.1 244 −2.32
7 M 64 12 OD 0.30 0.17 0.6 0.4 262 −0.54
OS 0.30 0.17 0.4 0.4 248 −0.64
8 M 62 11 OD 0.17 0.09 1.0 0.9 196 −6.73
OS 0.30 0.17 0.9 0.9 198 −5.72
RMS: root mean square.
MD: mean deviation.
Brazil) was used to confirm the posterior hyaloid removal;
if still present, it was detached by direct aspiration with
the vitrectomy probe with a vacuum rate set at 500mmHg.
Scleral indentation was performed and aspiration was reset
at 200mmHg for complete removal of the vitreous base and
identification of possible retinal breaks. In bilateral cases, the
same surgical technique was used 7 days later to treat the
fellow eye.
The questionnaire of vision quality (NEI VFQ-25) was
applied before and after PPV, in a 1-month interval. NEIVFQ-
25 includes 25 questions that measure different components
of visual function, with six additional optional items that
enhance the reliability of the near and distance activity sub-
scales. These were included in the Minimally Classic/Occult
Trial of the Anti-VEGF Antibody Ranibizumab in the Treat-
ment of Neovascular AMD (age-related macular degener-
ation) study and Anti-VEGF Antibody for the Treatment
of Predominantly Classic Choroidal Neovascularization in
AMD clinical trial [12]. The scores ranged from 0 (worst
vision) to 100 (best, perfect vision-related function). There
are 12 subscales: one general health subscale and 11 vision
subscales, including general vision, difficulties related to
near and distance vision activities, difficulties related to
driving, vision-specific dependency, social functioning, role
difficulties, limitations in peripheral and color vision, ocular
pain, and mental health issues related to vision. The overall
composite score was calculated using the mean of the sub-
scales, excluding the general health subscale.
A Portuguese version of the questionnaire was applied
and reliability was assessed using Cronbach’s alpha coeffi-
cient, intraclass correlation coefficient, and interrater reli-
ability coefficient. To estimate the power of the test, we
considered simple random sampling and normal distribution
for the VFQ-25 subscale scores. Given these assumptions,
the estimated power of the test was between 50 and 90%,
depending on the subscale [13].
The preoperative and postoperative NEI VFQ-25 scores
and UCVA using logarithm of the minimum angle of reso-
lution (LogMAR) charts were compared using the nonpara-
metric Wilcoxon test. 𝑃 < 0.05 was considered significant.
The analysis was performed using SPSS software v. 21.0 (IBM,
New York, USA).
3. Results
Sixteen eyes of eight patients were included in the analysis
and all patients had improvement in UCVA after vitrectomy.
All studied eyes were submitted to previous YAG-laser capsu-
lotomy during the 6-month evaluation before the vitrectomy.
Baseline data andUCVAvalues are shown inTable 1. All of the
refraction values ranged from −0.25 to +0.25 diopters with
no astigmatism preoperatively and did not change after PPV;
hence, there were no differences between UCVA and BCVA
values. Table 2 shows the changes in the postoperative VFQ-
25 scores on its subscales and the comparison between the
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Table 2: Results of the VFQ-25 subscales and uncorrected visual acuity (UCVA) used to compare the preoperative period to the postoperative
one.
Parameter PreoperativeMedian (range)
Postoperative
Median (range) 𝑃
1
𝑛
2
General health 75 (50–100) 75 (50–100) 0.157 2 (25%)
General vision 60 (40–80) 80 (60–100) 0.023∗ 6 (75%)
Ocular pain 81 (38–100) 81 (63–100) 0.180 2 (25%)
Near activities 75 (42–100) 92 (58–100) 0.043∗ 5 (63%)
Distance activities 67 (58–100) 100 (75–100) 0.041∗ 5 (63%)
Social functioning 94 (75–100) 100 (88–100) 0.083 3 (38%)
Mental health 75 (38–81) 94 (50–100) 0.011∗ 8 (100%)
Role difficulties 88 (25–100) 100 (75–100) 0.042∗ 5 (63%)
Dependency 100 (58–100) 100 (83–100) 0.102 3 (38%)
Driving 67 (50–67) 92 (75–100) 0.016∗ 7 (100%)
Color vision 100 (50–100) 100 (100–100) 0.317 1 (13%)
Peripheral vision 75 (50–100) 100 (75–100) 0.059 4 (50%)
UCVA (logMAR) 0.17 (0.09–0.30) 0.09 (0.00–0.17) 0.017
1Wilcoxon test.
2Number of patients that got better scores after surgery.
UCVA: uncorrected visual acuity.
∗
𝑃 < 0.05.
preoperative and postoperative scores of the VFQ-25. The
LogMAR UCVA levels are also presented (Tables 1 and 2).
VA significantly improved from a median value of 0.17
preoperatively to 0.09 postoperatively (𝑃 = 0.017) (Tables
1 and 2). All patients with symptomatic PVD confirmed by
ultrasonography (Figure 1) who underwent PPV reported not
only improvement of VA but also improvement regarding
halos, glare, and floaters (each of these symptoms was
reported preoperatively by all patients). The following post-
operative NEI VFQ-25 subscales median scores significantly
improved: general vision (from 60 preoperatively to 80
postoperatively, 𝑃 = 0.023), near activities (from 75 to 92,
𝑃 = 0.043), distance activities (from 67 to 100, 𝑃 = 0.041),
mental health (from 75 to 94, 𝑃 = 0.011), role difficulties
(from 88 to 100, 𝑃 = 0.042), and driving (from 67 to 92,
𝑃 = 0.016) (Table 2 and Figure 2).
At 6-month follow-up, there were no complications
reported; specifically, no cases of rhegmatogenous retinal
detachment and/or macular edema occurred in our series.
Only 2 eyes underwent surgical induction of PVD. In the
remaining 14 eyes, the posterior hyaloid was already detached
at the time of surgery.
4. Discussion
Vitreous floaters are common symptoms that are classically
treated by observation only [14]. Floaters may even be
considered physiologic and age-related. However, they can
be inconvenient and decrease the VA and visual quality
of many patients [2]. These symptoms may be exacerbated
by multifocal IOLs, since both PVD and these lenses are
known to be responsible for increasing light scattering in
ocular media [15, 16]. Diffractive multifocal IOLs generate
two images simultaneously on the retina [17].We hypothesize
Figure 1: Example of ultrasonography image showing symptomatic
PVD in one eye 7 months after multifocal IOL implantation in a
patient complaining of floaters, halos, and poor quality of vision.
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Figure 2: Boxplot of the preoperative and postoperative NEI VFQ-
25 scores in the subscales of general health (GH), general vision
(GV), ocular pain (OP), near activities (NA), distance activities
(DA), social functioning (SF), mental health (MH), role difficulties
(RD), dependency (DP), driving (DR), color vision (CV), and
peripheral vision (PV).
Journal of Ophthalmology 5
1
2
3
4
(a) (b)
Figure 3: (a) Drawing showing an eye with a multifocal IOL and PVD. The light rays first pass through the cornea and then the IOL. The
high density of the PVD causes dispersion of the light rays. (1) The light ray in black represents distance vision. (2) The light ray in red
represents near vision. (3) The wavy blue line represents vitreous detachment. (4) The gray arrows show dispersion of the light rays when
they pass through the dense vitreous causing halos, floaters, and blurred vision. (b) The drawing shows the light rays reaching the retina
without interference from the vitreous detachment after PPV, indicating the potential for good near and distance vision without glasses. The
red lines indicate the light rays for near vision.
that symptomatic PVD associated light scattering [1, 18,
19] enhances this phenomenon by diffracting light rays in
many directions thus worsening VA and quality of vision
(Figure 3(a)). When there are no media opacities (such as
after PPV), both near and far light rays can reach the retina
at the same point of focus (Figure 3(b)).
PPV is a procedure that is usually reserved for compli-
cated posterior segment disease. It has a well-known risk
profile and, justifiably, there is reluctance to perform this
surgery to treat floaters [2]. However, technological advances
in both instrumentation and techniques have made PPV a
much safer procedure [20, 21]. Small-gauge vitrectomy offers
the advantages of minimal invasiveness, reduced postoper-
ative inflammation and complications, and faster recovery
[21].
The surgical management of floaters with PPV remains
highly controversial among vitreoretinal surgeons. Plenty
of evidence suggests that quality of life is improved in
successfully operated patients [22–25].The real issue remains,
that is, the safety of this procedure [20, 26]. Induction of PVD
during surgery is a major risk factor for the development
of postoperative rhegmatogenous retinal detachment. In the
current small series, we tried to include only eyes with com-
plete PVD to reduce the risk of retinal detachment. However,
even with preoperative ultrasonographic examination, 12.5%
of eyes in our series still required intraoperative induction of
PVD.No complications developed 6months after vitrectomy.
However, we should remain cautious given the small sample
size and the relatively short follow-up. The authors think
that the inclusion of only cases of bilateral disease was
coincidental, or there is also the possibility that these patients
have more intense symptoms related to PVD.
The results of the current study demonstrate the benefits
of PPV in specific eyes with a multifocal IOL and symp-
tomatic PVD. A statistically significant (𝑃 = 0.017) improve-
ment in UCVA (Tables 1 and 2) was observed following PPV.
The authors chose to report UCVA instead of the most com-
mon BCVA levels because usually patients with a multifocal
IOL are expected to have a satisfactory good visual acuity
without the need to use glasses or contact lenses; also, all
patients presented no significant refractive error. All patients
reported improvement regarding halos, glare, and floaters.
To evaluate quality of vision, we compared the results of the
VFQ-25 before and after vitrectomy in eyes that underwent
previous bilateral multifocal IOL implantation (Table 2). The
results showed significantly (𝑃 < 0.05 for all comparisons)
improved postoperative VFQ-25 scores in all subscales tested
(near and distance activities, mental health, role difficulty,
and driving) (Table 2). A comparison between the VFQ-25
results in the pre- and postoperative periods at only 1-month
interval after vitrectomy was performed in order to avoid the
fact that binocular neurosensory adaptation could play a role
in vision improvement; additionally at least 6 months was
used as inclusion criteria since the initial symptoms, after the
cataract surgery, until the indication of vitreoretinal surgery.
Some limitations of the current study must be addressed:
first, the small number of patients enrolled, the short follow-
up period, and absence of control subjects, since this was
a pilot investigation; second, the lack of contrast sensitivity
data, which was not included since the main objective was
to observe the response of patients to surgery in terms of
visual acuity and quality of life (as measured by the VFQ-25);
third, the inclusion of posterior capsulotomy/capsulectomy
in all eyes (capsulotomy at the preoperative period using
the YAG-laser and capsulectomy during PPV). Previous
capsulotomy was performed because capsular opacification
may be related to the symptoms described [27]. Additionally,
we hypothesized that residual capsular fragments or residual
vitreous present at the posterior surface of the multifocal lens
could also be related to these symptoms reported. Finally,
the explanation of lack of wavefront analysis is based on
the argument that we believe the clinical exam, the absence
of astigmatism, and also the RMS value limit used (less
than 1.2) are enough evidences to exclude that possible
corneal problems, could be the cause of decrease in quality of
vision.
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Despite these, our preliminary results are exciting. To
the best of our knowledge, this is the first study to address
the importance of the posterior vitreous surgery in VA and
quality of vision in eyes implanted with bilateral multifocal
IOLs. On the basis of these preliminary data, it is reasonable
to conclude that the status of the vitreous is important in
patients whomay undergo multifocal IOL implantation. Pre-
operative evaluation of candidates for these intraocular lenses
implantations should include an assessment of the vitreous.
Patients with symptomatic PVD who are not satisfied with
their VA and quality of vision may benefit from small-gauge
PPV in specific situations reported. However, additional
clinical trials with large series of patients performed by
different surgeons are necessary to confirm these preliminary
observations.
Summary Statement
Pars plana vitrectomy improves visual acuity and quality of
vision in patients implantedwith amultifocal intraocular lens
who have clinically relevant posterior vitreous detachment
and are not satisfied with their vision.
Conflict of Interests
The authors have no financial or proprietary interest in any of
the products or techniques mentioned in this paper.
Acknowledgments
The current research was conducted with funding resources
provided by the following institutions in Brazil: Con-
selho Nacional de Pesquisa (CNPq) and Coordenac¸a˜o de
Aperfeic¸oamento de Pessoal de Nı´vel Superior (CAPES). A
complete listing of participating members of PACORES is
as follows. The following investigators belong to the Pan-
American Collaborative Retina Study Group (PACORES): L.
Wu (principal investigator, PI), Instituto de Cirugia Ocular,
San Jose´, Costa Rica; J. F. Arevalo (PI), King Khalid Eye
SpecialistHospital, Riyadh, SaudiArabia, and theWilmer Eye
Institute, Johns Hopkins University, Baltimore, MD, USA;
M. A. Serrano (PI) and A. F. Lasave, Clinica Oftalmolo´gica
Centro Caracas and the Arevalo-Coutinho Foundation for
Research in Ophthalmology, Caracas, Venezuela; M. Farah
(PI), M. Maia, F. M. Penha, and E. B. Rodrigues, Depar-
tamento de Oftalmologia, Instituto da Visa˜o, Universidade
Federal de Sa˜o Paulo, Sa˜o Paulo, Brazil; V. Morales-Canton
(PI), J. Fromow-Guerra, J. L. Guerrero-Naranjo, and J.
Dalma-Weiszhausz, Asociacio´n para Evitar la Ceguera en
Me´xico,MexicoCity,Mexico;H.Quiroz-Mercado (PI) andR.
Velez-Montoya, University of Colorado, School of Medicine,
Denver, Colorado; F. J. Rodriguez (PI), F. E. Gomez, and
A.C. Brieke, FundacionOftalmologicaNacional, Universidad
del Rosario, Bogota, Colombia; M. H. Berrocal (PI) and V.
Cruz-Villegas, University of Puerto Rico, San Juan, Puerto
Rico; F. Graue-Wiechers (PI), D. Lozano-Rechy, and E. Ariza-
Camacho, Fundacio´n Conde Valenciana, Mexico City, Mex-
ico; J. A. Roca (PI) and R. G. Chico, Cl´ınica Ricardo Palma,
Lima, Peru; M. J. Saravia (PI), A. Schlaen, A. Lupinacci,
and M. N. Gabin, Hospital Universitario Austral, Buenos
Aires, Argentina; M. Avila (PI) and L. Carla, Departamento
de Oftalmologia, Universidade Federal de Goia´s, Goiaˆnia,
Brazil; J. Cardillo (PI), Hospital de Olhos Araraquara and
Universidade de Sa˜o Paulo, Sa˜o Paulo, Brazil; J. Verdaguer
(PI), C. Carpentier, J. I. Verdaguer, and G. Sepu´lveda, Funda-
cion Oftalmolo´gica Los Andes, Santiago de Chile, Chile; A.
Alezzandrini (PI), B. Garcia, and G. Bregliano, OFTALMOS,
Ca´tedra de Oftalmologı´a, Universidad de Buenos Aires,
Buenos Aires, Argentina; G. Alvira (PI), P. Flor, and F.
Jaramillo, Hospital Metropolitano, Quito, Ecuador; M. Diaz-
Llopis (PI), R. Gallego-Pinazo, P. Udaondo, and D. Salom,
Hospital La Fe, Universidad de Valencia, Spain; M. Figueroa
(PI), I. Contreras, and D. Ruiz-Casas, Departamento de
Retina, Hospital Universitario Ramo´n y Cajal and VISSUM
Madrid Mirasierra de Oftalmologı´a Integral, Madrid, Spain.
References
[1] R. Y. Foos, “Posterior vitreous detachment,” Transactions—
American Academy of Ophthalmology and Otolaryngology, vol.
76, no. 2, pp. 480–497, 1972.
[2] R. J. Foos and N. C. Wheeler, “Vitreoretinal juncture. Synchysis
senilis and posterior vitreous detachment,”Ophthalmology, vol.
89, no. 12, pp. 1502–1512, 1982.
[3] R. E. Coffee, A. C. Westfall, G. H. Davis, W. F. Mieler, and
E. R. Holz, “Symptomatic posterior vitreous detachment and
the incidence of delayed retinal breaks: case series and meta-
analysis,” American Journal of Ophthalmology, vol. 144, no. 3,
pp. 409–413, 2007.
[4] A. Mirshahi, F. Hoehn, K. Lorenz, and L.-O. Hattenbach, “Inci-
dence of posterior vitreous detachment after cataract surgery,”
Journal of Cataract andRefractive Surgery, vol. 35, no. 6, pp. 987–
991, 2009.
[5] F. Vega, F. Alba-Bueno, and M. S. Milla´n, “Energy distribution
between distance and near images in apodized diffractive
multifocal intraocular lenses,” Investigative Ophthalmology &
Visual Science, vol. 52, no. 8, pp. 5695–5701, 2011.
[6] M. R. Santhiago, M. V. Netto, J. Barreto Jr., B. A. F. Gomes,
A. Schaefer, and N. Kara-Junior, “Wavefront analysis and
modulation transfer function of three multifocal intraocular
lenses,” Indian Journal of Ophthalmology, vol. 58, no. 2, pp. 109–
113, 2010.
[7] J. C. Prieto and M. J. Bautista, “Visual outcomes after implan-
tation of a refractive multifocal intraocular lens with a +3.00 D
addition,” Journal of Cataract and Refractive Surgery, vol. 36, no.
9, pp. 1508–1516, 2010.
[8] J. S. M. Chang, J. C. M. Ng, and S. Y. F. Lau, “Visual outcomes
and patient satisfaction after presbyopic lens exchange with
a diffractive multifocal intraocular lens,” Journal of Refractive
Surgery, vol. 28, no. 7, pp. 468–474, 2012.
[9] P. Sood andM.A.Woodward, “Patient acceptability of the tecnis
multifocal intraocular lens,” Clinical Ophthalmology, vol. 5, no.
1, pp. 403–410, 2011.
[10] C. P. Bautista, D. C. Gonza´lez, A. C. Go´mez, and J. A. C. Bescos,
“Evolution of visual performance in 250 eyes implanted with
Tecnis ZM900 multifocal IOL,” European Journal of Ophthal-
mology, vol. 19, no. 5, pp. 762–768, 2009.
Journal of Ophthalmology 7
[11] M. Yoshino, M. Inoue, N. Kitamura, and H. Bissen-Miyajima,
“Diffractive multifocal intraocular lens interferes with intraop-
erative view,” Clinical Ophthalmology, vol. 4, no. 1, pp. 467–469,
2010.
[12] I. J. Sun˜er, G. T. Kokame, E. Yu, J. Ward, C. Dolan, and N. M.
Bressler, “Responsiveness of NEI VFQ-25 to changes in visual
acuity in neovascular AMD: validation studies from two phase
3 clinical trials,” Investigative Ophthalmology & Visual Science,
vol. 50, no. 8, pp. 3629–3635, 2009.
[13] L. M. Sima˜o, M. A. Lana-Peixoto, C. R. Arau´jo, M. A. Mor-
eira, and A. L. Teixeira, “The Brazilian version of the 25-
Item National Eye Institute Visual Function Questionnaire:
translation, reliability and validity,” Arquivos Brasileiros de
Oftalmologia, vol. 71, no. 4, pp. 540–546, 2008.
[14] F. Mart´ınez-Sanz, J. I. Velarde, P. Casuso, and J. N. F. Dez-
Cotero, “Surgical solution to vitreous floaters visual problem,”
Archivos de la Sociedad Espan˜ola de Oftalmologı´a, vol. 84, no. 5,
pp. 259–262, 2009.
[15] D. P. Pinero, D. Ortiz, and J. L. Alio, “Ocular scattering,”
Optometry & Vision Science, vol. 87, no. 9, pp. E682–E696, 2010.
[16] M. J. Langeslag,M. van derMooren, G.H. Beiko, and P. A. Piers,
“Impact of intraocular lens material and design on light scatter:
in vitro study,” Journal of Cataract & Refractive Surgery, vol. 40,
no. 12, pp. 2120–2127, 2014.
[17] J. Ji, X. Huang, X. Fan, and M. Luo, “Visual performance of
acrysof ReSTOR compared with a monofocal intraocular lens
following implantation in cataract surgery,” Experimental and
Therapeutic Medicine, vol. 5, no. 1, pp. 277–281, 2013.
[18] J. J. Kanski, “Complications of acute posterior vitreous detach-
ment,” The American Journal of Ophthalmology, vol. 80, no. 1,
pp. 44–46, 1975.
[19] M. Castilla-Marti, T. J. T. P. van den Berg, and M. D. de
Smet, “Effect of vitreous opacities on straylight measurements,”
Retina, vol. 35, no. 6, pp. 1240–1246, 2015.
[20] C. P. Wilkinson, “Safety of vitrectomy for floaters—how safe is
safe?” American Journal of Ophthalmology, vol. 151, no. 6, pp.
919.e1–920.e1, 2011.
[21] S. Khanduja, A. Kakkar, S. Majumdar, R. Vohra, and S. Garg,
“Small gauge vitrectomy: recent update,” Oman Journal of
Ophthalmology, vol. 6, no. 1, pp. 3–11, 2013.
[22] Y. M. Delaney, A. Oyinloye, and L. Benjamin, “Nd:YAG vitreol-
ysis and pars plana vitrectomy: surgical treatment for vitreous
floaters,” Eye, vol. 16, no. 1, pp. 21–26, 2002.
[23] S. Schulz-Key, J.-O. Carlsson, and S. Crafoord, “Longterm
follow-up of pars plana vitrectomy for vitreous floaters: com-
plications, outcomes and patient satisfaction,”Acta Ophthalmo-
logica, vol. 89, no. 2, pp. 159–165, 2011.
[24] J. Sebag, “Floaters and the quality of life,” American Journal of
Ophthalmology, vol. 152, no. 1, pp. 3.e1–4.e1, 2011.
[25] K. F. de Nie, N. Crama, M. A. D. Crama, B. J. Klevering, and
C. J. F. Boon, “Pars plana vitrectomy for disturbing primary
vitreous floaters: clinical outcome and patient satisfaction,”
Graefe’s Archive for Clinical and Experimental Ophthalmology,
vol. 251, no. 5, pp. 1373–1382, 2013.
[26] H. S. Tan, M. Mura, S. Y. L. Oberstein, and H. M. Bijl, “Safety
of vitrectomy for floaters,” American Journal of Ophthalmology,
vol. 151, no. 6, pp. 995–998, 2011.
[27] V. C. Shah, C. Russo, R. Cannon, R. Davidson, and M. J. Tar-
avella, “Incidence of Nd:YAG capsulotomy after implantation
of AcrySof multifocal and monofocal intraocular lenses: a case
controlled study,” Journal of Refractive Surgery, vol. 26, no. 8, pp.
565–568, 2010.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
